Navigation Links
Efavirenz in Medical News

Merck Cuts Price of Efavirenz for Developing Countries Again

Merck & Co has cut the price of efavirenz 600mg tablets (Stocrin) for developing countries that qualify for its access programme//, the company announced yesterday. It is the second price cut in a year, and crucially, it will make the branded version of efavirenz cheaper than a generic impor...

Brazilian President Silva Issues Compulsory License for Merck's Antiretroviral Efavirenz

Brazilian President Luiz Inacio Lula da Silva on Friday issued a compulsory license to produce a lower-cost, generic version of Merck's antiretroviral Efavirenz, the AP/Forbes reports. World Trade Organization regulations allow governments to declare a "national emergency" and issue compul...

HIV integrase inhibitor effective for patients beginning antiretroviral treatment

...reached that goal, compared with 82 percent of the efavirenz group. Half the raltegravir group reached the e...k four, compared with less than 20 percent for the efavirenz group. In addition, the raltegravir group encounte...t of Health and Human Services currently recommend efavirenz or a protease inhibitor, in combination with tenof...

Tools for more accurate dosage of drugs against HIV/AIDS and malaria

...om Zimbabwe with HIV/AIDS, and showed that a reduction in the daily dose of efavirenz from 600 mg to 400 mg can reduce the risk of undesired effects in those aff...effects of anti-HIV/AIDS drugs. Calculations showed that treatment in which efavirenz was combined with other pharmaceutical substances was more effective than t...

Study Supports Popular HIV Drug Regimen

...hers found that the combination of a drug known as efavirenz (also known as Sustiva) plus two NRTI drugs did a ...e-third of those who took lopinavir-ritonavir plus efavirenz -- two drugs instead of the usual three -- and in...'s a simpler treatment for patients," she said. efavirenz isn't for everyone, Riddler cautioned. "A certain ...

Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007

... $78 million in the same period in 2006. Total revenue for the SUSTIVA(R) Franchise includes sales of SUSTIVA(R), as well as revenue from bulk efavirenz included in the combination therapy ATRIPLA(TM), which is sold through a joint venture in the U.S. and Canada with Gilead Sciences, Inc. -- S...

Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial

...e properties. These include: potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a p...

Brazil Government New Health Offer

...tributing free drugs and condoms in his new AIDS program angered the international drug company Merck. Merck offered to cut the price of its AIDS drug efavirenz to about $1 per pill but Temporao decided to break Merck's patent and buy a cheaper substitute from India. His blunt style is reaching beyond ...

Thailand Unfazed As US Worries Over Copyright Violations

...emporarily suspend patent protections on medicines to safeguard public health. Thailand has issued compulsory licenses for AIDS drugs Kaletra and efavirenz and popular heart disease medicine Plavix. The government plans to import generic versions of the drugs from India, but could also choose to manufactu...

Brazil Opts for Indian Drugs Bypassing Merck

...S pharmaceutical giant Merck's patent on AIDS drug efavirenz and opted for a cheaper generic alternative from ... Brazil will be able to import generic versions of efavirenz from three companies in India - and the price for ...ating with Merck for three years to bring down the efavirenz price. Lula had criticized Merck for charg...
Efavirenz in Medical Technology

Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay

...assay demonstrated an overall improvement in Selzentry efficacy relative to efavirenz (the control arm of the trial). In the new retrospective analysis of the ME...duals achieved HIV-1 RNA <50 copies/mL at week 48 in both the Selzentry and efavirenz arms of the study. "The data presented this week demonstrate the value of...

Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference

... President and CEO. "We look forward to further evaluating RDEA806 and are on track to begin a Phase 2b study comparing once daily doses of RDEA806 to efavirenz (SUSTIVA(R), Stocrin(R)) in first-line patients receiving background treatment with Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), in t...

Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008

...g studied in phase III trials, achieved an undetectable viral load (<50 HIV-1 RNA copies/mL) at week 96 compared with 71 percent of patients receiving efavirenz (EFV). Of patients receiving the 75 mg and 150 mg doses of TMC278, 72 percent and 71 percent achieved an undetectable viral load, respectively. "NNR...

Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV

...V-1, are now recruiting patients. The global trials will compare the efficacy, safety and tolerability of TMC278 (25 mg) once daily oral tablet versus efavirenz (EFV), each coadministered with a background regimen of two nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs), in treatment-naive HIV-...

Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing

...dvantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)) and other currently available NNRTIs; a high genetic barrier to resistance; no reproductive toxicity based on animal studies; the potenti...

Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program

...vantages. These include: the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb); a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral dosing regimen;...

Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load

...dvantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (SUSTIVA(R)) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral ...

Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus

...candidate, RDEA806, is a potent inhibitor of HIV, including the most common efavirenz resistant viruses. Oral dosing with RDEA806 achieves trough levels in human...t a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb); a high genetic barrier to resistance; t...

IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients

...activity against established NNRTI-resistant clinical isolates. Compared to efavirenz (Sustiva(R)), the emergence of IDX899-resistant HIV-1 isolates was slower a...ted in-vitro with IDX899 were different from those selected with efavirenz. efavirenz appeared to be active against IDX899 resistant viruses and IDX899 remained ...

European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection

...of their first antiretroviral treatment regimen. efavirenz is marketed by Bristol-Myers Squibb Company (NYSE:...nd, Germany, Italy, Spain and the United Kingdom). efavirenz is commercialized by Merck & Co., Inc, through its...s-like behavior, but it could not be determined if efavirenz was the cause. Patients with serious psychiatric a...
Efavirenz in Biological News

Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults

...V-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less l...re significantly less likely than those started on efavirenz to achieve high treatment adherence." Nachega, ...erse transcriptase inhibitor such as nevirapine or efavirenz in resource limited settings. Nearly 67 percent of...
Efavirenz in Biological Technology

Monogram Announces 2008 Third Quarter Financial Results

...assay demonstrated an overall improvement in Selzentry efficacy relative to efavirenz (the control arm of the trial). In the new retrospective analysis of the ME...duals achieved HIV-1 RNA <50 copies/mL at week 48 in both the Selzentry and efavirenz arms of the study. "Given the efficacy of existing first line treatments,...

Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company

... $82 million in the same period in 2007. Total revenue for the SUSTIVA(R) Franchise includes sales of SUSTIVA(R), as well as revenue from bulk efavirenz included in the combination therapy ATRIPLA(TM), which is sold through a joint venture in the U.S., Canada and Europe with Gilead Sciences, ...

Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses

...dvantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (SUSTIVA(R)) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral ...

Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections

...e properties. These include: potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a ...
Other Tags
(Date:4/1/2015)... 2015 ScooterDirect.com is a one stop ... improve their customers’ lifestyle using electric mobility scooters, power ... needs of the people, they provide mobility scooters at ... independent and enjoy their freedom. Scooterdirect.com is offering Pride ... prices. , One of the team members ...
(Date:4/1/2015)... April 01, 2015 Patients with inoperable ... to them, thanks to the FDA’s approval of CRS-207’s ... the full story on the Surviving Mesothelioma website. ... a modified version of the bacteria that causes the ... its manufacturer grant funding and other incentives to support ...
(Date:4/1/2015)... Denver, Colorado (PRWEB) April 01, 2015 ... a member of the American Cannabis Exchange and will ... ACE Marketplace. Native Roots joins the exchange as one ... holding sixty-eight licenses and operating fifteen stores in 9 ... 2015. , “We are excited to have ...
(Date:4/1/2015)... Mateo, CA (PRWEB) April 01, 2015 ... $100,200 in athletics grants from California Casualty . ... free or reduced-cost lunches and subsequently have fewer and ... is named after California Casualty Chairman Emeritus Thomas R. ... field translated to the classroom. Since its inception ...
(Date:4/1/2015)... 01, 2015 The dearth of ... are set to retire in the next five ... demand for laboratory automation. The application of advanced ... it ensures timely progress and efficiency with minimal ... lab automation in high-throughput screening, combinatorial chemistry, automated ...
Breaking Medicine News(10 mins):Health News:ScooterDirect.com Offering Pride Go Go Traveller Elite 3 Wheel Scooter 2Health News:Orphan Drug Approval May Mean New Treatment Option for Mesothelioma, According to Surviving Mesothelioma 2Health News:Amercanex, Native Roots form Exclusive Relationship to facilitate Wholesale Business 2Health News:Amercanex, Native Roots form Exclusive Relationship to facilitate Wholesale Business 3Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 2Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 3Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 4Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 5Health News:Laboratory Accessories Market Worth $504.7 Million by 2020 – New Research Report by MarketsandMarkets 2Health News:Laboratory Accessories Market Worth $504.7 Million by 2020 – New Research Report by MarketsandMarkets 3
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
Other Contents